Applications of CRISPR technology in cellular immunotherapy

Abstract

SummaryCRISPR technology has transformed multiple fields, including cancer and immunology. CRISPR‐based gene editing and screening empowers direct genomic manipulation of immune cells, opening doors to unbiased functional genetic screens. These screens aid in the discovery of novel factors that regulate and reprogram immune responses, offering novel drug targets. The engineering of immune cells using CRISPR has sparked a transformation in the cellular immunotherapy field, resulting in a multitude of ongoing clinical trials. In this review, we discuss the development and applications of CRISPR and related gene editing technologies in immune cells, focusing on functional genomics screening, gene editing‐based cell therapies, as well as future directions in this rapidly advancing field.

High-throughput CRISPR technology: a novel horizon for solid organ transplantation

“…Fortunately, high-throughput CRISPR screening has dramatically accelerated the effective targets in various immunocytes ( 2 ). However, its application in solid organ transplantation is limited.…”

Golden age of immunoengineering

“…CRISPR/Cas has become the most essential tool in genome engineering. Chen and colleagues 10 summarize the latest developments and experimental considerations in using CRISPR/Cas for unbiased functional screens in immune cells. They also discussed critical advances in creating more potent therapeutic immune cell therapies using CRISPR (Figure 2B).…”

Targeting ferroptosis in gastric cancer: Strategies and opportunities

“…The primary treatment approach for early‐stage GC involves endoscopic resection, whereas advanced GC is typically managed through a combination of surgery and chemotherapy 13 . In recent years, tumor immunotherapy has proven to be a promising approach for the treatment of GC, involving the utilization of monoclonal antibodies targeting tumors, immune checkpoint blockers, gene editing‐based T‐cell therapies, and chimeric antigen receptor (CAR) T cells, which have opened up new avenues for therapeutic intervention 14–16 . Despite recent advancements in GC treatment, the prognosis for patients with advanced GC remains unfavorable 17 .…”

“…13 In recent years, tumor immunotherapy has proven to be a promising approach for the treatment of GC, involving the utilization of monoclonal antibodies targeting tumors, immune checkpoint blockers, gene editing-based T-cell therapies, and chimeric antigen receptor (CAR) T cells, which have opened up new avenues for therapeutic intervention. [14][15][16] Despite recent advancements in GC treatment, the prognosis for patients with advanced GC remains unfavorable. 17 An increasing body of evidence suggests that ferroptosis plays a significant role, especially in GC, encompassing its roles in diagnosis, treatment, biological functions, and drug resistance.…”